Ballentine Partners LLC Raises Stake in Eli Lilly and Company (NYSE:LLY)

Ballentine Partners LLC raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 16,981 shares of the company’s stock after purchasing an additional 601 shares during the quarter. Ballentine Partners LLC’s holdings in Eli Lilly and Company were worth $15,044,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Heritage Oak Wealth Advisors LLC raised its position in shares of Eli Lilly and Company by 109.8% during the third quarter. Heritage Oak Wealth Advisors LLC now owns 860 shares of the company’s stock valued at $762,000 after buying an additional 450 shares during the last quarter. Busey Bank raised its position in shares of Eli Lilly and Company by 1.2% during the third quarter. Busey Bank now owns 23,331 shares of the company’s stock valued at $20,670,000 after buying an additional 269 shares during the last quarter. Cross Staff Investments Inc raised its position in shares of Eli Lilly and Company by 0.6% during the third quarter. Cross Staff Investments Inc now owns 2,555 shares of the company’s stock valued at $2,264,000 after buying an additional 15 shares during the last quarter. E. Ohman J or Asset Management AB raised its position in shares of Eli Lilly and Company by 10.5% during the third quarter. E. Ohman J or Asset Management AB now owns 72,995 shares of the company’s stock valued at $64,669,000 after buying an additional 6,915 shares during the last quarter. Finally, West Michigan Advisors LLC raised its position in shares of Eli Lilly and Company by 1.8% during the third quarter. West Michigan Advisors LLC now owns 2,622 shares of the company’s stock valued at $2,323,000 after buying an additional 46 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on LLY. Barclays lifted their price objective on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a research report on Wednesday, July 10th. Truist Financial boosted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research report on Thursday, October 10th. BMO Capital Markets boosted their price target on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. Guggenheim boosted their price target on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a research report on Monday, September 16th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,013.41.

Eli Lilly and Company Stock Up 0.1 %

NYSE:LLY opened at $892.51 on Friday. Eli Lilly and Company has a 1-year low of $547.61 and a 1-year high of $972.53. The company has a 50-day moving average of $920.32 and a 200 day moving average of $860.96. The firm has a market cap of $848.27 billion, a PE ratio of 109.92, a price-to-earnings-growth ratio of 3.24 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The company had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. As a group, research analysts anticipate that Eli Lilly and Company will post 14.05 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.